Suitability of the PAXgene™ system to stabilize bone marrow RNA in imatinib-resistant patients with chronic myeloid leukemia

Clinical Chemistry and Laboratory Medicine

Volumn 46, Issue 3, 2008, Pages 318-322

  Ernst, Thomas ^a   Hoffmann, Jana ^a   Erben, Philipp ^a   Hehlmann, Rüdiger ^a   Hochhaus, Andreas ^a   Müller, Martin C ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

BCR ABL mRNA; Blood; Bone marrow; PAXgene ; RNA stabilization

Indexed keywords

ABELSON KINASE; BCR ABL PROTEIN; BETA GLUCURONIDASE; COMPLEMENTARY DNA; IMATINIB; RNA; BCR ABL TYROSINE KINASE; BCR-ABL TYROSINE KINASE; PIPERAZINE DERIVATIVE; PROTEIN TYROSINE KINASE; PYRIMIDINE DERIVATIVE;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; BONE MARROW; CANCER PATIENT; CANCER RESISTANCE; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE MUTATION; GENE SEQUENCE; GENE TECHNOLOGY; GENETIC TRANSCRIPTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HOUSEKEEPING GENE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA DEGRADATION; RNA EXTRACTION; RNA STABILITY; RNA STABILIZATION SYSTEM; BLOOD; CHEMISTRY; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; METHODOLOGY; MIDDLE AGED; MUTATION; PROTEIN TERTIARY STRUCTURE; STANDARD;

ADULT; AGED; AGED, 80 AND OVER; BONE MARROW; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUCURONIDASE; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; MUTATION; PIPERAZINES; PROTEIN STRUCTURE, TERTIARY; PROTEIN-TYROSINE KINASES; PYRIMIDINES; REFERENCE STANDARDS; RNA STABILITY; RNA, NEOPLASM;

EID: 39849086542     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2008.086     Document Type: Article

References (21)

1. Baccarani M, Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2006;108:1809-20.
2. Hughes T, Deininger M, Hochhaus A, Branford S, Radich J, Kaeda J, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 2006;108: 28-37.
3. Müller MC, Hördt T, Paschka P, Merx K, La Rosee P, Hehlmann R, et al. Standardization of preanalytical factors for minimal residual disease analysis in chronic myelogenous leukemia. Acta Haematol 2004;112:30-3.
4. Müller MC, Merx K, Weisser A, Kreil S, Lahaye T, Hehlmann R, et al. Improvement of molecular monitoring of residual disease in leukemias by bedside RNA stabilization. Leukemia 2002;16:2395-9.
5. Thörn I, Olsson-Stromberg U, Ohlsen C, Jonsson AM, Klangby U, Simonsson B, et al. The impact of RNA stabilization on minimal residual disease assessment in chronic myeloid leukemia. Haematologica 2005;90: 1471-6.
6. Breit S, Nees M, Schaefer U, Pfoersich M, Hagemeier C, Muckenthaler M, et al. Impact of pre-analytical handling on bone marrow mRNA gene expression. Br J Haematol 2004;126:231-43.
7. Rainen L, Oelmueller U, Jurgensen S, Wyrich R, Ballas C, Schram J, et al. Stabilization of mRNA expression in whole blood samples. Clin Chem 2002;48:1883-90.
8. Prezeau N, Silvy M, Gabert J, Picard C. Assessment of a new RNA stabilizing reagent (Tempus Blood RNA) for minimal residual disease in onco-hematology using the EAC protocol. Leuk Res 2006;30:569-74.
9. Øvstebø R, Lande K, Kierulf P, Haug KB. Quantification of relative changes in specific mRNAs from frozen whole blood - methodological considerations and clinical implications. Clin Chem Lab Med 2007;45:171-6.
10. Imbeaud S, Graudens E, Boulanger V, Barlet X, Zaborski P, Eveno E, et al. Towards standardization of RNA quality assessment using user-independent classifiers of microcapillary electrophoresis traces. Nucleic Acids Res 2005; 33:e56.
11. Cross NC, Feng L, Bungey J, Goldman JM. Minimal residual disease after bone marrow transplant for chronic myeloid leukaemia detected by the polymerase chain reaction. Leuk Lymphoma 1993;11:39-43.
12. Emig M, Saussele S, Wittor H, Weisser A, Reiter A, Willer A, et al. Accurate and rapid analysis of residual disease in patients with CML using specific fluorescent hybridization probes for real time quantitative RT-PCR. Leukemia 1999;13:1825-32.
13. Beillard E, Pallisgaard N, van der Velden VH, Bi W, Dee R, van der Schoot E, et al. Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - a Europe against cancer program. Leukemia 2003;17:2474-86.
14. Ernst T, Erben P, Müller MC, Paschka P, Schenk T, Hoffmann J, et al. Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib. Haematologica. In press.
15. Lin F, Goldman JM, Cross NC. A comparison of the sensitivity of blood and bone marrow for the detection of minimal residual disease in chronic myeloid leukaemia. Br J Haematol 1994;86:683-5.
16. Kantarjian HM, Talpaz M, Cortes J, O'Brien S, Faderl S, Thomas D, et al. Quantitative polymerase chain reaction monitoring of BCR-ABL during therapy with imatinib mesylate (STI571; gleevec) in chronic-phase chronic myelogenous leukemia. Clin Cancer Res 2003;9:160-6.
17. Stock W, Yu D, Karrison T, Sher D, Stone RM, Larson RA, et al. Quantitative real-time RT-PCR monitoring of BCR-ABL in chronic myelogenous leukemia shows lack of agreement in blood and bone marrow samples. Int J Oncol 2006;28:1099-103.
18. Müller MC, Saglio G, Lin F, Pfeifer H, Press RD, Tubbs RR, et al. An international study to standardize the detection and quantitation of BCR-ABL transcripts from stabilized peripheral blood preparations by quantitative RT-PCR. Haematologica 2007;92:970-3.
19. Müller MC, Erben P, Saglio G, Gottardi E, Guldborg Nyvold C, Schenk T, et al. Harmonization of BCR-ABL mRNA quantification using a uniform multifunctional control plasmid in 37 international laboratories. Leukemia 2007 Oct 18 [Epub ahead of print].
20. Langebrake C, Gunther K, Lauber J, Reinhardt D. Pre-analytical mRNA stabilization of whole bone marrow samples. Clin Chem 2007;53:587-93.
21. Kagedal B, Lindqvist M, Farneback M, Lenner L, Peterson C. Failure of the PAXgene blood RNA system to maintain mRNA stability in whole blood. Clin Chem Lab Med 2005;43:1190-2.